馃敟 DeLLphi-305 shook the room at #ESMO26 and what a spectacular discussion by @StephenVLiu
Outstanding data deserve an equally outstanding discussion, and Stephen delivered! 馃憦
馃挜 OS HR 0.42 , unprecedented impact in ES-SCLC!
Key questions: CNS efficacy, long-term survival, predictive biomarkers and optimal treatment sequencing.
Encouraging outpatient feasibility and improved monitoring requirements.
And one crucial message: global access to this breakthrough treatment must become a priority.
Spectacular science, spectacular discussion! A truly unforgettable ESMO Plenary!
#ESMOAmbassadors #ESMO26 #DeLLphi305 #SCLC #LungCancer
30 views 路 2 likes 路 0 reposts 路 0 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Alfredo Addeo MD 路 x.com